RxDoctor Payments Data

Jeffrey Charnov, MD

Interventional Pain Medicine · Houston, TXNPI 1629060405

Payments from drug & device makers

$1,074in general payments, 2019–2025

Across 54 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Innovation Technologies Inc$96
  • Collegium Pharmaceutical, Inc.$85
  • AbbVie$83
  • Pfizer$83
  • Scilex Pharmaceuticals Inc.$78
  • Biodelivery Sciences International, Inc.$68
  • plus $581 from 20 others

What the payments were for

  • Food & beverage$1,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,074 in reported general payments places this provider in the 15th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$222,642
Medicare patients
233
Services billed
3,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,349$73,053
BelbucaBuprenorphine Hcl73$55,995
MovantikNaloxegol Oxalate44$21,324
Xtampza ErOxycodone Myristate25$20,245
Buprenorphine77$18,816
NucyntaTapentadol Hcl12$14,689
Fentanyl160$13,582
Pregabalin494$12,272
Lidocaine49$12,173
Gabapentin689$11,555
Morphine Sulfate ErMorphine Sulfate400$10,511
Emgality PenGalcanezumab-Gnlm12$8,122
Tramadol Hcl763$6,720
ZtlidoLidocaine11$6,284
LinzessLinaclotide12$5,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$85$90,928110 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$23$22,995219 claims
Redhill Biopharma Inc.Movantik$24$21,32444 claims
Scilex Pharmaceuticals Inc.Ztlido$78$6,28411 claims
AbbVieLinzess$83$5,92212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →